A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury - Pavel I. Pilipenko; Anna A. Ivanova; Yulia V. Kotsiubinskaya; Vera N. Grigoryeva; Alexey Y. Khrulev; Anatoly V. Skorokhodov; Maxim M. Gavrik; Nona N. Mkrtchan; Marek Majdan; Peter Valkovic; Daria Rabarova; Suzanne Barker-Collo; et al. (PLoS ONE)